AIM: To study the effect of probiotic consumption on the faecal microbiota during and after antibiotic exposure. METHODS: A randomized, double-blind, placebo-controlled, parallel group study with a two species probiotic combination [Lactobacillus acidophilus (L. acidophilus) ATCC 700396 and Bifidobacterium lactis (B. lactis) ATCC SD5220] on healthy adults during and after antibiotic treatment (amoxicillin 875 and 125 mg clavulanate). The dominant faecal microbiota was studied by real time-polymerase chain reaction to determine if this probiotic preparation could facilitate restoring the microbiota to its pre-antibiotic state and influence the prevalence of beta-lactam resistance. Gastrointestinal symptoms were recorded by questionnaire and Bristol stool scale. RESULTS: Subjects on the probiotic combination had significantly higher faecal counts of L. acidophilus ATCC 700396 and B. lactis at day 8 (end of antibiotic treatment period) vs those on placebo. Furthermore, subjects on the probiotic combination had significantly higher faecal counts of L. acidophilus ATCC 700396 and B. lactis at Day 15 (end of probiotic treatment) vs those on placebo. Lactobacillus counts remained stable in the probiotic group over the course of the study, while Clostridium XIV group was higher at the end of the study and closer to baseline levels; this in contrast to the placebo group. Beta-lactam resistance in creased after antibiotic exposure and was not different between both treatment groups. Gastrointestinal symptoms were generally mild and did not differ between the treatment groups, which correlates with the generally small changes in the microbiota. CONCLUSION: Consumption of the probiotic combination mainly leads to an increase in the faecal levels of the species included in the preparation.
RCT Entities:
AIM: To study the effect of probiotic consumption on the faecal microbiota during and after antibiotic exposure. METHODS: A randomized, double-blind, placebo-controlled, parallel group study with a two species probiotic combination [Lactobacillus acidophilus (L. acidophilus) ATCC 700396 and Bifidobacterium lactis (B. lactis) ATCC SD5220] on healthy adults during and after antibiotic treatment (amoxicillin 875 and 125 mg clavulanate). The dominant faecal microbiota was studied by real time-polymerase chain reaction to determine if this probiotic preparation could facilitate restoring the microbiota to its pre-antibiotic state and influence the prevalence of beta-lactam resistance. Gastrointestinal symptoms were recorded by questionnaire and Bristol stool scale. RESULTS: Subjects on the probiotic combination had significantly higher faecal counts of L. acidophilus ATCC 700396 and B. lactis at day 8 (end of antibiotic treatment period) vs those on placebo. Furthermore, subjects on the probiotic combination had significantly higher faecal counts of L. acidophilus ATCC 700396 and B. lactis at Day 15 (end of probiotic treatment) vs those on placebo. Lactobacillus counts remained stable in the probiotic group over the course of the study, while Clostridium XIV group was higher at the end of the study and closer to baseline levels; this in contrast to the placebo group. Beta-lactam resistance in creased after antibiotic exposure and was not different between both treatment groups. Gastrointestinal symptoms were generally mild and did not differ between the treatment groups, which correlates with the generally small changes in the microbiota. CONCLUSION: Consumption of the probiotic combination mainly leads to an increase in the faecal levels of the species included in the preparation.
Authors: Susan F Plummer; Iveta Garaiova; Tinnu Sarvotham; Simon L Cottrell; Stephanie Le Scouiller; Mark A Weaver; James Tang; Philippa Dee; John Hunter Journal: Int J Antimicrob Agents Date: 2005-07 Impact factor: 5.283
Authors: Anna Engelbrektson; Joshua R Korzenik; Arlyn Pittler; Mary E Sanders; Todd R Klaenhammer; Gregory Leyer; Christopher L Kitts Journal: J Med Microbiol Date: 2009-05 Impact factor: 2.472
Authors: A C Ouwehand; S J M ten Bruggencate; A J Schonewille; E Alhoniemi; S D Forssten; I M J Bovee-Oudenhoven Journal: Br J Nutr Date: 2013-08-12 Impact factor: 3.718
Authors: Daniel J Merenstein; Tina P Tan; Aleksey Molokin; Keisha Herbin Smith; Robert F Roberts; Nawar M Shara; Mihriye Mete; Mary Ellen Sanders; Gloria Solano-Aguilar Journal: Gut Microbes Date: 2015
Authors: Nathalia Ramori Farinha Wagner; Marilia Rizzon Zaparolli Ramos; Ligia de Oliveira Carlos; Magda Rosa Ramos da Cruz; Cesar Augusto Taconeli; Alcides José Branco Filho; Luis Sergio Nassif; Maria Eliana Madalozzo Schieferdecker; Antônio Carlos Ligocki Campos Journal: Obes Surg Date: 2020-08-11 Impact factor: 4.129
Authors: Chad W MacPherson; Olivier Mathieu; Julien Tremblay; Julie Champagne; André Nantel; Stéphanie-Anne Girard; Thomas A Tompkins Journal: Sci Rep Date: 2018-07-25 Impact factor: 4.379
Authors: Karen T Elvers; Victoria J Wilson; Ashley Hammond; Lorna Duncan; Alyson L Huntley; Alastair D Hay; Esther T van der Werf Journal: BMJ Open Date: 2020-09-21 Impact factor: 2.692